Identification
Instrument name
CURETIS
Symbol
CURE
ISIN code
NL0011509294
Exchange / Market
Euronext
Trading location
Amsterdam
Brussels
Products family
Stocks
Capitalization compartment
Compartment B
ICB
Medical Equipment
Website address
http://www.curetis.com
Operation
IPO date
IPO price
EUR 10.00
Issue type
Initial Public offering
Cat├ęgorie
IPO
Price range
EUR 9.50 - EUR 12.00
Capital raised
40

Company profile

Curetis specializes in the development and marketing of molecular diagnostic systems for hospitals and laboratories. The products are devoted to detecting severe infectious diseases as well as resistance to anti-biotics in hospitalized patients. The diagnostic solutions (Unyvero Solution) enable rapid multi-parameter pathogen and antibiotic resistance detection in only a few hours, a process that today can take up to days or even weeks with other techniques. Syndromic tests for diagnosing lower respiratory tract infections /pneumonia as well as implant and tissue infections are commercially available.

Source: Cofisem - Last Update: 02 Aug 2019
Key Executives
Chief Executive Officer Oliver Schacht
Chief Operations Officer Johannes Bacher
Investor Relations Director Lisa Schneckenburger
Source: Cofisem - Last Update: 02 Aug 2019
Key figures
Millenium 2018 2017 2016 2015 2014
Net sales 1,419 1,187 1,306 2,087 275
Income from ordinary activities 1,419 1,187 1,306 2,087 275
Operating income -22,911 -18,567 -15,233 -12,051 -10,132
Cost (net) of financial indebtedness -1,079 -621
Equity-accounted companies' contribution to results
Net profit from discontinued activities
Net income -23,745 -19,498 -15,172 13,840 -12,434
Net income (Group share) -23,745 -19,498 -15,172 13,840 -12,434
Fiscal year end 12.18 12.17 12.16 12.15 12.14
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 02 Aug 2019
Shareholder information
LSP Curetis Pooling 20.67 %
C Partners Holding 9.14 %
Aviva plc 4.94 %
HBM BioCapital II Management 4.63 %
Roche Finanz AG 4.62 %
Federal Republic of Germany 4.43 %
CD-Venture GmbH 3.40 %
Forbion Capital Fund II Cooperatief 2.89 %
BioMedPartners 2.02 %
Source: Cofisem - Last Update: 15 Jan 2019